VRTX logo
Vertex Pharmaceuticals Incorporated(VRTX)
$528.03—

Latest analyst action Page refreshed hourly; analyst feeds refreshed dailyAbout this data

Consensus

Buy3.79 / 524 ratings · Strong Buy 0 · Buy 20 · Hold 3 · Sell 1 · Strong Sell 0
Avg target $568.67+8.0%Median $582.50High $665.00Low $350.0018 targets in the last 12 months1 rating older than 2 years not counted

Price vs average target

Revenue and EPS estimates

ReportedConsensus estimates
Fiscal periodFY2023Dec '23FY2024Dec '24FY2025Dec '25FY2026Dec '26FY2027Dec '27FY2028Dec '28FY2029Dec '29FY2030Dec '30
Revenue (B)9.8711.0112.0013.2314.6216.4718.5620.45
Growth YoY+10.5%+11.5%+9.0%+10.3%+10.5%+12.6%+12.7%+10.2%
High estimate–––13.4016.1317.6819.4021.38
Low estimate–––13.1713.8315.2217.8919.72
Analysts–––131312106
EPS, adjusted15.220.2918.4118.6721.1125.2430.0834.15
Growth YoY+2.2%−98.1%+6248.3%+1.4%+13.1%+19.5%+19.2%+13.5%
High estimate–––19.1122.9229.3731.8636.16
Low estimate–––17.4518.6220.6528.6732.55
Analysts–––1112724

Consensus mean of analyst estimates. EPS is adjusted (street) EPS, the basis analysts forecast; annual actuals are the sum of the four reported quarters. Growth compares with the same period a year earlier; n/m where the prior period was a loss.

Brokers

25 firms active in the last 12 months
FirmAnalystRatingPrev ratingTargetPrev targetChgUpsideDate
UBSMichael YeeBuyBuy$615.00$585.00+5%+17%Sep 28
JefferiesAkash TewariBuy · Dec 2024Hold$640.00$580.00+10%+22%Sep 23
H.C. WainwrightAndrew FeinBuy · Mar 2026Buy$641.00$591.00+8%+22%Sep 22
Goldman Sachs–Buy · Jan 2024 · not countedBuy$653.00$598.00+9%+24%Sep 1
Morgan StanleyTerence FlynnOverweight · May 2026Overweight$665.00$616.00+8%+26%Sep 1
BernsteinJeffrey WalchOutperform · May 2026Outperform$608.00$572.00+6%+15%Aug 11
Wolfe ResearchAndy ChenOutperform · Jan 2026Peer Perform$562.00$576.00−2%+7%Aug 10
BarclaysEliana MerleOverweightOverweight$617.00$615.000%+17%Aug 5
Truist FinancialDanielle BrillBuyBuy$565.00$560.00+1%+7%Aug 5
Canaccord Genuity–HoldHold$442.00$436.00+1%−16%Aug 4
Cantor FitzgeraldCarter GouldOverweightOverweight$595.00$590.00+1%+13%Aug 4
Stifel NicolausPaul MatteisHold · Feb 2026Hold$500.00$466.00+7%−5%Aug 4
TD Cowen–BuyBuy––––Aug 4
RBC CapitalBrian AbrahamsOutperformOutperform$570.00$543.00+5%+8%Jul 7
Robert W. Baird–UnderperformUnderperform$350.00$240.00+46%−34%Jul 7
Maxim Group–BuyHold––––Mar 18
B of A Securities–BuyBuy––––Mar 10
Citigroup–BuyBuy––––Mar 10
Oppenheimer–OutperformOutperform––––Mar 10
BMO CapitalEvan David SeigermanOutperform · Aug 2025Outperform$600.00$530.00+13%+14%Mar 2
ScotiabankLouise ChenSector PerformSector Perform$558.00$442.00+26%+6%Feb 13
Evercore ISICory KasimovOutperformOutperform$530.00$438.00+21%+1%Jan 23
Leerink Partners–OutperformOutperform$525.00$456.00+15%0%Dec 29, 2025
Wells Fargo–OverweightOverweight––––Dec 10, 2025
JP Morgan–OverweightOverweight––––Oct 8, 2025
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.